Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6998387 | 0.83 | F2 (0.44) | CHRNB2CHRNA4HSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL19597443 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4KAT2BHTR7LTA4H | |
| SCHEMBL12754891 | 0.80 | KDM4E (0.45) | HSD17B10LTA4HGRM4HTTALDH1A1 | |
| SCHEMBL1509521 | 0.80 | CHRNB2 (0.47) | CHRNB2CHRNA4KAT2BHTR7LTA4H | |
| SCHEMBL16334317 | 0.79 | CHRNB2 (0.50) | CHRNB2CHRNA4KAT2BHTR7LTA4H | |
| SCHEMBL323831 | 0.78 | ALDH1A1 (0.48) | HSD17B10GRM4HTTALDH1A1L3MBTL1 | |
| SCHEMBL238407 | 0.78 | HTR7 (0.53) | CHRNB2CHRNA4KAT2BHTR7HTR1B | |
| SCHEMBL28311734 | 0.76 | KDM4E (0.49) | CHRM2ALDH1A1 | |
| SCHEMBL238514 | 0.76 | ALDH1A1 (0.49) | HSD17B10HTTALDH1A1L3MBTL1 | |
| SCHEMBL29174339 | 0.73 | GRM4 (0.41) | CHRM2GRM4HTTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | PROXIMAGEN LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-8835439-B2 | Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases | PROXIMAGEN LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | BIOVITRUM AB (PUBL) (SE) | 2013-06-20 | — | — | US | disclosed |
| US-8410113-B2 | (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof | BIOVITRUM AB (PUBL) (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-12 | — | — | US | disclosed |
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-05 | — | — | US | disclosed |
| US-8030316-B2 | Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine | BIOVITRUM AB (PUBL) (SE) | 2011-10-04 | — | — | US | disclosed |
| US-7820677-B2 | Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20100256374-A1 | NOVEL PROCESS | BIOVITRUM AB, A SWEDEN CORPORATION | 2010-10-07 | — | — | US | disclosed |
| EP-1645558-B1 | Piperazinylpyrazines as serotonin 5-HT2C receptor modulators | BIOVITRUM AB PUBL (SE) | 2008-06-11 | — | — | EP | disclosed |
| US-7129354-B2 | Process for the preparation of stable acid addition salt of 2,3-disubstituted pyrazine compounds | BIOVITRUM AB (SE) | 2006-10-31 | — | — | US | disclosed |
| EP-1529043-B1 | Process for the preparation of 2-methyl piperazine derivatives. | BIOVITRUM AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060142578-A1 | Novel process | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-06-29 | — | — | US | disclosed |
| EP-1645558-A1 | Piperazinylpyrazines as serotonin 5-HT2C receptor modulators | BIOVITRUM AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1529043-A1 | NOVEL PROCESS | Biovitrum AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040038981-A1 | Novel Process | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-26 | — | — | US | disclosed |
| WO-2004000829-A1 | NOVEL PROCESS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | SUCNR1, HTR5A, HTR2C | CHRNB2 1029/4885CHRNA4 572/4885HSD17B10 419/4885 |
| US-20100256374-A1 | NOVEL PROCESS | HTR1A, TPH1, HTR5A | CHRNB2 240/4885CHRNA4 140/4885HSD17B10 398/4885 |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | HTR2C, HTR5A, HTR2A | CHRNB2 252/4885CHRNA4 187/4885HSD17B10 732/4885 |
| US-20040038981-A1 | Novel Process | HTR1A, TPH1, HTR1B | CHRNB2 258/4885CHRNA4 115/4885HSD17B10 373/4885 |
| US-20060142578-A1 | Novel process | HTR1A, TPH1, HTR5A | CHRNB2 216/4885CHRNA4 140/4885HSD17B10 480/4885 |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | CHRNB2 252/4885CHRNA4 187/4885HSD17B10 732/4885 |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | CHRNB2 252/4885CHRNA4 187/4885HSD17B10 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.